SMARCA2 and neoplasm: Small molecule inhibitors of the ATPase activity of BRG1 and BRM have been developed, which repress BRG1/BRM‐dependent gene expression, induce cell differentiation and inhibit the in vitro growth of solid and haematopoietic tumour cells, as well as the in vivo growth of these tumours [28, 29, 30].